Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 and Venetoclax in Acute Myeloid Leukemia
NCT04657081Phase 2Active, not recruiting
- Sponsor
- Taiho Oncology
- Start
- Feb 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of decitabine in acute myeloid leukemia (AML), sponsored by Taiho Oncology. Primary endpoints: Area Under the Curve from Time Zero to 24 Hours, Maximum Plasma Concentration and 1 more. Started Feb 2021; status: active, not recruiting.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04657081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04657081.